Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 107-112

  Lencioni, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Hepatocellular carcinoma; Image guided ablation; Molecular targeted therapies; Transarterial chemoembolization

Indexed keywords

ALCOHOL; TALAPORFIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER SURGERY; CHEMOEMBOLIZATION; DRUG DELIVERY SYSTEM; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MOLECULAR THERAPY; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 77954494287     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315238     Document Type: Review

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bruix J, Llovet JM: Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614-616.
3. Bruix J, Sherman M, Llovet JM, et al: EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference: European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
4. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. Llovet JM, Di Bisceglie AM, Bruix J, et al, Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
6. Lencioni R, Crocetti L: Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 2007; 10: 38-46.
7. Lencioni R, Crocetti L: Image-guided thermal ablation of hepatocellular carcinoma: Crit Rev Oncol Hematol 2008; 66: 200-207.
8. Lencioni R, Bartolozzi C, Caramella D, et al: Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: analysis of prognostic factors in 105 Western patients. Cancer 1995; 76: 1737-1746.
9. Lencioni R, Pinto F, Armillotta N, et al: Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: 514-519. (Pubitemid 127538668)
10. Khan KN, Yatsuhashi H, Yamasaki K, et al: Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269-278.
11. Koda M, Murawaki Y, Mitsuda A, et al: Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000; 88: 529-537.
12. Kuang M, Lu MD, Xie XY, et al: Ethanol ab lation of hepatocellular carcinoma up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology 2009;253:552-561 .
13. Lencioni R, Allgaier HP, Cioni D, et al: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
14. Lin SM, Lin CJ, Lin CC, et al: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma = 4 cm. Gastroenterology 2004; 127: 1714-1723.
15. Shiina S, Teratani T, Obi S, et al: A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
16. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156.
17. Brunello F, Veltri A, Carucci P, et al: Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735.
18. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524.
19. Cho YK, Kim JK, Kim MY, Rhim H, Han JK: Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-459.
20. Lu DS, Yu NC, Raman SS, et al: Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954-960.
21. Livraghi T, Solbiati L, Meloni MF, et al: Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 26: 441-451.
22. Ebara M, Okabe S, Kita K, et al: Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20- year observation. J Hepatol 2005; 43: 458-464.
23. Shibata T, Iimuro Y, Yamamoto Y, et al: Small hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 331-337.
24. Wang S, Keltner L, Winship J, Lee W: A phase 1/2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. Proc 2009 ASCO Annual Meeting, abstr e15684.
25. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
26. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
27. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
28. Varela M, Real MI, Burrel M, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481.
29. Lencioni R, Malagari K, Vogl T, et al: A randomised phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. ASCO GI Proceedings, San Francisco, January 2009.
30. Lencioni R, Cioni D, Crocetti L, et al: Earlystage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous imageguided radiofrequency ablation. Radiology 2005; 234: 961-967.
31. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
32. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
33. www.clinicaltrials.gov (accessed August 14, 2009).
34. Wang B, Xu H, Gao ZQ, et al: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-529.
35. Virmani S, Rhee TK, Ryu RK, et al: Comparison of hypoxia-inducible factor-1α expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008; 19: 1483-1489.